Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,326 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials.
Fallah J, Zhang L, Amatya A, Gong Y, King-Kallimanis B, Bhatnagar V, Weinstock C, Suzman DL, Agrawal S, Chang E, Anscher MS, Chi DC, Xu JX, Brewer JR, Brave MH, Hadadi M, Theoret MR, Kluetz PG, Goldberg KB, Ibrahim A, Tang S, Pazdur R, Beaver JA, Amiri-Kordestani L, Singh H. Fallah J, et al. Among authors: agrawal s. Lancet Oncol. 2021 Sep;22(9):1230-1239. doi: 10.1016/S1470-2045(21)00334-X. Epub 2021 Jul 23. Lancet Oncol. 2021. PMID: 34310904
FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer.
Fallah J, Agrawal S, Gittleman H, Fiero MH, Subramaniam S, John C, Chen W, Ricks TK, Niu G, Fotenos A, Wang M, Chiang K, Pierce WF, Suzman DL, Tang S, Pazdur R, Amiri-Kordestani L, Ibrahim A, Kluetz PG. Fallah J, et al. Among authors: agrawal s. Clin Cancer Res. 2023 May 1;29(9):1651-1657. doi: 10.1158/1078-0432.CCR-22-2875. Clin Cancer Res. 2023. PMID: 36469000 Free PMC article. Clinical Trial.
A U.S. Food and Drug Administration-pooled Analysis of Frontline Combination Treatment Survival Benefits by Risk Groups in Metastatic Renal Cell Carcinoma.
Lee D, Gittleman H, Weinstock C, Suzman D, Bloomquist E, Agrawal S, Brave M, Brewer J, Fallah J, Singh H, Tang S, Ibrahim A, Pazdur R, Beaver JA, Amiri-Kordestani L. Lee D, et al. Among authors: agrawal s. Eur Urol. 2023 Oct;84(4):373-378. doi: 10.1016/j.eururo.2023.05.030. Epub 2023 Jun 2. Eur Urol. 2023. PMID: 37271635
A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma.
Chang E, Zhou J, Song C, Gittleman H, Fernandes L, Weinstock C, Atkins MB, Agrawal S, Sridhara R, Gormley N, Tang S, Suzman DL, Amiri-Kordestani L, Kluetz PG, Pazdur R, Rini BI, McDermott DF, Regan MM. Chang E, et al. Among authors: agrawal s. Clin Cancer Res. 2024 Aug 1;30(15):3282-3286. doi: 10.1158/1078-0432.CCR-23-3719. Clin Cancer Res. 2024. PMID: 38416426
FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma.
Maguire WF, Lee D, Weinstock C, Gao X, Bulik CC, Agrawal S, Chang E, Hamed SS, Bloomquist EW, Tang S, Pazdur R, Kluetz PG, Amiri-Kordestani L, Suzman DL. Maguire WF, et al. Among authors: agrawal s. Clin Cancer Res. 2024 May 15;30(10):2011-2016. doi: 10.1158/1078-0432.CCR-23-3738. Clin Cancer Res. 2024. PMID: 38441576 Free PMC article.
Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis.
Fallah J, Xu J, Weinstock C, Gao X, Heiss BL, Maguire WF, Chang E, Agrawal S, Tang S, Amiri-Kordestani L, Pazdur R, Kluetz PG, Suzman DL. Fallah J, et al. Among authors: agrawal s. J Clin Oncol. 2024 May 10;42(14):1687-1698. doi: 10.1200/JCO.23.02105. Epub 2024 Mar 14. J Clin Oncol. 2024. PMID: 38484203
4,326 results